Physician profile
Brian K Locker
NPI 1679540868
$2,671.34
in general payments reported to CMS, 2019-2025
31 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $81.87 · 2021: $294 · 2022: $696 · 2023: $455 · 2024: $352 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.18 |
| Education | $139.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $315.15 | 2019-2023 | |
| Novo Nordisk INC | $242.01 | 2019-2023 | |
| Abbvie INC. | $196.30 | 2019-2022 | |
| Astellas Pharma US INC | $194.81 | 2023-2025 | Veozah |
| Aspira Women'S Health INC | $164.10 | 2021-2024 | Ova1 |
| Sumitomo Pharma America, INC. | $138.92 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $135.75 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $131.58 | 2019-2025 | Aptima, Myosure Tissue Removal Device, Thinprep 2000 Processor |
| Myovant Sciences INC. | $112.43 | 2022 | |
| Daiichi Sankyo INC. | $111.23 | 2019-2025 | Injectafer |
| Therapeuticsmd, INC. | $111.22 | 2019-2022 | |
| Coopersurgical, INC. | $96.14 | 2022-2025 | Paragard T 380a, Fisherbrand Disposable Liquid Infant Heel Warmer, Mara Console |
| Agile Therapeutics, INC. | $91.71 | 2022-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $86.13 | 2019-2025 | |
| Millicent US INC | $80.48 | 2024 | Femring, Intrarosa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $63.35 | 2022-2025 | Nexplanon |
| Baxter Healthcare | $56.78 | 2025 | Tisseel |
| Channel Medsystems, INC. | $53.06 | 2022-2023 | |
| Scynexis, INC. | $43.52 | 2022 | |
| Biogen, INC. | $38.06 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $33.63 | 2023-2024 | |
| Shield Therapeutics INC | $32.08 | 2022-2023 | Accrufer |
| Medtronic, INC. | $26.55 | 2021 | |
| Becton, Dickinson and Company | $23.78 | 2019 | |
| Smith+Nephew, INC. | $19.40 | 2025 | Stravix Pl |
| Medicem INC. | $17.10 | 2021 | |
| Boston Scientific Corporation | $16.91 | 2019 | |
| Merck Sharp & Dohme LLC | $14.18 | 2019 | |
| Gynesonics, INC. | $12.81 | 2022 | |
| Dysis Medical, INC. | $12.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Locker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.